Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07559396
PHASE1
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
Sponsor: Incyte Corporation
View on ClinicalTrials.gov
Summary
This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with severe renal impairment or end stage renal disease.
Official title: A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2026-05-15
Completion Date
2027-01-04
Last Updated
2026-04-30
Healthy Volunteers
No
Conditions
Interventions
DRUG
INCB123667
Group 1: Single dose administered orally. Group 2: Two single doses administered orally.